Terms: = Kidney tumors AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Staging
18 results:
1. Clinical significance and expression of PUMA, MCL-1, and p53 in human renal cell carcinoma and para-carcinoma tissues.
Xia HB; Cui HW; Su L; Zhang ZH; Yang XY; Ning SQ; Su XL
Genet Mol Res; 2017 Jul; 16(3):. PubMed ID: 28692117
[TBL] [Abstract] [Full Text] [Related]
2. Gain of 1q As a Prognostic Biomarker in Wilms tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
Chagtai T; Zill C; Dainese L; Wegert J; Savola S; Popov S; Mifsud W; Vujanić G; Sebire N; Le Bouc Y; Ambros PF; Kager L; O'Sullivan MJ; Blaise A; Bergeron C; Mengelbier LH; Gisselsson D; Kool M; Tytgat GA; van den Heuvel-Eibrink MM; Graf N; van Tinteren H; Coulomb A; Gessler M; Williams RD; Pritchard-Jones K
J Clin Oncol; 2016 Sep; 34(26):3195-203. PubMed ID: 27432915
[TBL] [Abstract] [Full Text] [Related]
3. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.
Ingels A; Hew M; Algaba F; de Boer OJ; van Moorselaar RJ; Horenblas S; Zondervan P; de la Rosette JJ; Pilar Laguna Pes M
World J Urol; 2017 Jan; 35(1):81-87. PubMed ID: 27207480
[TBL] [Abstract] [Full Text] [Related]
4. Review of prognostic and predictive aspects of mutated tp53 in Wilms' tumor biology with morphological report and molecular analysis of 37-year-old man's nephroblastoma.
Wincewicz A; Kowalik A; Zięba S; Kopczyński J; Góźdź S; Sulkowski S
Pol J Pathol; 2016; 67(4):307-312. PubMed ID: 28547957
[TBL] [Abstract] [Full Text] [Related]
5. p53 Immunohistochemistry expression in Wilms tumor: a prognostic tool in the detection of tumor aggressiveness.
Franken J; Lerut E; Van Poppel H; Bogaert G
J Urol; 2013 Feb; 189(2):664-70. PubMed ID: 23036984
[TBL] [Abstract] [Full Text] [Related]
6. Significance of P-glycoprotein, p53, and survivin expression in renal cell carcinoma.
Baytekin F; Tuna B; Mungan U; Aslan G; Yorukoglu K
Urol Oncol; 2011; 29(5):502-7. PubMed ID: 19945306
[TBL] [Abstract] [Full Text] [Related]
7. Biomarkers in renal cell carcinoma.
McGuire BB; Fitzpatrick JM
Curr Opin Urol; 2009 Sep; 19(5):441-6. PubMed ID: 19584732
[TBL] [Abstract] [Full Text] [Related]
8. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
Klatte T; Seligson DB; LaRochelle J; Shuch B; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Pantuck AJ; Belldegrun AS
Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):894-900. PubMed ID: 19240241
[TBL] [Abstract] [Full Text] [Related]
9. Surveillance for renal cell carcinoma: why and how? When and how often?
Klatte T; Lam JS; Shuch B; Belldegrun AS; Pantuck AJ
Urol Oncol; 2008; 26(5):550-4. PubMed ID: 18774472
[TBL] [Abstract] [Full Text] [Related]
10. mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype.
Christoph F; Hinz S; Kempkensteffen C; Schostak M; Schrader M; Miller K
J Urol; 2007 Dec; 178(6):2655-9. PubMed ID: 17945286
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic biomarkers in renal cell carcinoma: relevance of DNA ploidy in predicting disease-related survival.
Pinto AE; Monteiro P; Silva G; Ayres JV; Soares J
Int J Biol Markers; 2005; 20(4):249-56. PubMed ID: 16398407
[TBL] [Abstract] [Full Text] [Related]
12. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma.
Kim HL; Seligson D; Liu X; Janzen N; Bui MH; Yu H; Shi T; Belldegrun AS; Horvath S; Figlin RA
J Urol; 2005 May; 173(5):1496-501. PubMed ID: 15821467
[TBL] [Abstract] [Full Text] [Related]
13. Using protein expressions to predict survival in clear cell renal carcinoma.
Kim HL; Seligson D; Liu X; Janzen N; Bui MH; Yu H; Shi T; Figlin RA; Horvath S; Belldegrun AS
Clin Cancer Res; 2004 Aug; 10(16):5464-71. PubMed ID: 15328185
[TBL] [Abstract] [Full Text] [Related]
14. Primary percutaneous approach to upper urinary tract transitional cell carcinoma.
Jabbour ME; Smith AD
Urol Clin North Am; 2000 Nov; 27(4):739-50. PubMed ID: 11098771
[TBL] [Abstract] [Full Text] [Related]
15. Risk-based management: current concepts of treating malignant solid tumors of childhood.
Grosfeld JL
J Am Coll Surg; 1999 Oct; 189(4):407-25. PubMed ID: 10509467
[TBL] [Abstract] [Full Text] [Related]
16. Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an immunohistochemical study correlating grading, staging, and proliferation markers.
Haitel A; Wiener HG; Blaschitz U; Marberger M; Susani M
Cancer; 1999 Apr; 85(7):1593-8. PubMed ID: 10193951
[TBL] [Abstract] [Full Text] [Related]
17. Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival.
Rey A; Lara PC; Redondo E; Valdés E; Apolinario R
Cancer; 1997 Jun; 79(11):2178-85. PubMed ID: 9179065
[TBL] [Abstract] [Full Text] [Related]
18. Flow cytometric and immunohistochemical correlations in high incidence human solid tumors.
Danesi DT; Spanò M; Antonini F; Altavista P; Catalano P; Cordelli E; Pasqualetti P; Santacroce C; Toscano MG; Mecozzi A; Fabiano A
Tumori; 1997; 83(3):689-97. PubMed ID: 9267490
[TBL] [Abstract] [Full Text] [Related]
